The DOI matches its Crossref record.
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
Abstract
The Li-Fraumeni cancer predisposition syndrome is associated with germline TP53 mutations in the majority of families. We have investigated cancer incidence in 34 Li-Fraumeni families, according to their constitutional TP53 mutation status. Families with germline missense mutations in the core DNA binding domain showed a more highly penetrant cancer phenotype than families with other TP53 mutations or no mutation. Cancer phenotype in families carrying such mutations was characterized by a higher cancer incidence and earlier ages at diagnosis, especially of breast cancer and brain tumours, compared with families carrying protein truncating or other inactivating mutations (P=0.03 for all cancers, P=0.006 for breast cancers, P=0.05 for brain tumours). Proband cancers showed significantly younger ages at diagnosis in those with missense mutations in the DNA binding domain than in those with protein inactivating mutations (P=0.031). In individuals with the former type of mutation, there was a significantly lower proportion of tumours which showed loss of the wild-type TP53 allele (P=0.004). These results are consistent with observations in experimental systems which demonstrate that certain mutations exhibit gain of function and/or dominant-negative properties. Our results support an enhanced oncogenic potential for such mutations in human populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In Li-Fraumeni syndrome (LFS), individuals with TP53 missense mutations show a higher cancer incidence and an earlier age of tumor onset than individuals with truncating or splicing mutations (Birch, et al., 1998).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Birch, et al., 1998
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A. M., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,143
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 721
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S. S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Ribeiro, R. C., Sandrini, F., Figueiredo, B., Zambetti, G. P., Michalkiewicz, E., Lafferty, A. R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161479898 · Cited by 541
Malkin, D. M. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 529
Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. L., & Eeles, R. A. (2003) · PubMed · Cited by 480
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
Birch, J. M., Alston, R. D., McNally, R. J., Evans, D. G. R., Kelsey, A. M., Harris, M., Eden, O. B., & Varley, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204621 · Cited by 467
Self-citationGermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 432
Self-citationHighly penetrant hereditary cancer syndromes
Nagy, R. S., Sweet, K. M., & Eng, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207714 · Cited by 399
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 356
Willis, A. C., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 342
Genomic instability — the engine of tumorigenesis?
Sieber, O. M., Heinimann, K., & Tomlinson, I. P. M. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1170 · Cited by 326
Daly, M. B., Pal, T., Maxwell, K. N., Churpek, J. E., Kohlmann, W. K., Al‐Hilli, Z., Arun, B., Buys, S. S., Cheng, H. H., Domchek, S. M., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0051 · Cited by 320
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
Hanel, W. G., Marchenko, N. D., Xu, S., Yu, S., Weng, W., & Moll, U. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.17 · Cited by 278
Li-Fraumeni syndrome: cancer risk assessment and clinical management
McBride, K. A., Ballinger, M. L., Killick, E., Kirk, J., Tattersall, M. H. N., Eeles, R. A., Thomas, D. M., & Mitchell, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.41 · Cited by 286
Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors
Varley, J. M., McGown, G., Thorncroft, M., James, L. A., Margison, G. P., Forster, G., Evans, D. G. R., Harris, M., Kelsey, A. M., & Birch, J. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302575 · Cited by 266
Self-citationSpectrum and Risk of Neoplasia in Werner Syndrome: A Systematic Review
Lauper, J. M., Krause, A. J., Vaughan, T. L., & Monnat, R. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059709 · Cited by 234
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Germline p53 Mutations in a Cohort with Childhood Sarcoma: Sex Differences in Cancer Risk
Hwang, S., Lozano, G., Amos, C. I., & Strong, L. C. (2003) · The American Journal of Human Genetics · doi:10.1086/374567 · Cited by 229
Cadwell, C., & Zambetti, G. P. (2001) · Gene · doi:10.1016/s0378-1119(01)00696-5 · Cited by 231
Beyond BRCA: New hereditary breast cancer susceptibility genes
Economopoulou, P., Dimitriadis, G., & Psyrri, A. K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.008 · Cited by 239
20 years studying p53 functions in genetically engineered mice
Donehower, L. A., & Lozano, G. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2731 · Cited by 196
Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen, M. G., & Slootweg, P. J. (2000) · PubMed · Cited by 193
Development of Spontaneous Mammary Tumors in BALB/c p53 Heterozygous Mice
Kuperwasser, C., Hurlbut, G. D., Kittrell, F. S., Dickinson, E. S., Laucirica, R., Medina, D., Naber, S. P., & Jerry, D. J. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64853-5 · Cited by 188
Mutant p53 mediates survival of breast cancer cells
Lim, L. Y., Vidnovic, N., Ellisen, L. W., & Leong, C.-O. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605335 · Cited by 181
Clinical implications of germline mutations in breast cancer: TP53
Schon, K. R., & Tischkowitz, M. D. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4531-y · Cited by 156
Gastric cancer in individuals with Li-Fraumeni syndrome
Masciari, S., Dewanwala, A., Stoffel, E. M., Lauwers, G. Y., Zheng, H. W., Achatz, M. I., Riegert‐Johnson, D. L., Foretová, L., da Silva, E. M., DiGianni, L. M., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821628b6 · Cited by 148
TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study
Wunder, J. S., Gökgöz, N., Parkes, R. K., Bull, S. B., Eskandarian, S., Davis, A. M., Beauchamp, C. P., Conrad, E. U., Grimer, R. J., Healey, J. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.074 · Cited by 141
Dearth, L. R., Hua, Q., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 139
Early onset HER2‐positive breast cancer is associated with germline TP53 mutations
Melhem‐Bertrandt, A., Bojadzieva, J., Ready, K. J., Obeid, E. I., Liu, D. D., Gutierrez‐Barrera, A. M., Litton, J. K., Olopade, O. I., Hortobágyi, G. N., Strong, L. C., et al. (2011) · Cancer · doi:10.1002/cncr.26377 · Cited by 137
Wendt, C., & Margolin, S. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1529428 · Cited by 144
Comparison ofp53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
Gökgöz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., & Andrulis, I. L. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8 · Cited by 125
Li‐Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition
Valdez, J. M., Nichols, K. E., & Kesserwan, C. A. (2016) · British Journal of Haematology · doi:10.1111/bjh.14461 · Cited by 124
Muto, M., Hitomi, Y., Ohtsu, A., Ebihara, S., Yoshida, S., & Esumi, H. (2000) · Gut · doi:10.1136/gut.47.2.256 · Cited by 121
Recognition and Management of Hereditary Breast Cancer Syndromes
Thull, D. L., & Vogel, V. G. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-13 · Cited by 118
Cutaneous melanoma susceptibility and progression genes
DESNOO, F., & Hayward, N. K. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.12.033 · Cited by 117
Translational advances regarding hereditary breast cancer syndromes
Gage, M. M., Wattendorf, D. J., & Henry, L. R. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.21856 · Cited by 118
Prevalence of Early Onset Colorectal Cancer in 397 Patients With Classic Li–Fraumeni Syndrome
Wong, P., Verselis, S. J., Garber, J. E., Schneider, K. A., DiGianni, L. M., Stockwell, D. H., Li, F. P., & Syngal, S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.014 · Cited by 111
Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Kim, M., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 113
Shen, H., Zheng, Y., Sturgis, E. M., Spitz, M. R., & Wei, Q. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00117-9 · Cited by 107
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome
Palmero, E. I., Achatz, M. I., Ashton‐Prolla, P., Olivier, M., & Hainaut, P. L. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333bf00 · Cited by 105
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53
Xiong, S., Tu, H., Kollareddy, M., Pant, V., Li, Q., Zhang, Y., Jackson, J. G., Suh, Y., Elizondo-Fraire, A. C., Yang, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404139111 · Cited by 102
Chompret, A. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01361-x · Cited by 104
P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development
Velletri, T., Xie, N., Wang, Y., Huang, Y., Yang, Q., Chen, X., Chen, Q., Shou, P., Gan, Y., Cao, G., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.367 · Cited by 93
Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators
Roemer, K. (1999) · Biological Chemistry · doi:10.1515/bc.1999.108 · Cited by 86
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
Salmón, A. S., Amikam, D., Sodha, N., Davidson, S., Basel‐Vanagaite, L., Eeles, R. A., Abeliovich, D., & Peretz, T. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.05.001 · Cited by 80
Birch, J. M. (1999) · Archives of Disease in Childhood · doi:10.1136/adc.80.1.1 · Cited by 79
Self-citationInactivation and Inducible Oncogenic Mutation of p53 in Gene Targeted Pigs
Leuchs, S., Saalfrank, A., Merkl, C., Flisikowska, T., Edlinger, M., Durkovic, M., Rezaei, N., Kurome, M., Zakhartchenko, V., Kessler, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043323 · Cited by 76
Molecular Diagnosis of Early Pancreatic Ductal Adenocarcinoma in High-Risk Patients
Wong, T., Howes, N., Threadgold, J., Smart, H. L., Lombard, M. G., Gilmore, I. T., Sutton, R., Greenhalf, W., Ellis, I., & Neoptolemos, J. P. (2001) · Pancreatology · doi:10.1159/000055852 · Cited by 70
High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort
Mitchell, G., Ballinger, M. L., Wong, S. Q., Hewitt, C., James, P. A., Young, M., Cipponi, A., Pang, T. W.-Y., Goode, D. L., Dobrovic, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069026 · Cited by 66
Marutani, M., Tonoki, H., Tada, M., Takahashi, M., Kashiwazaki, H., Hida, Y., Hamada, J. I., Asaka, M., & Moriuchi, T. (1999) · PubMed · Cited by 66
Birch, J. M., Alston, R. D., Quinn, M. J., & Kelsey, A. M. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.08.006 · Cited by 65
Self-citationCharacterization of germline TP53 splicing mutations and their genetic and functional analysis
Varley, J. M., Attwooll, C. L., White, G. R. M., McGown, G., Thorncroft, M. R., Kelsey, A. M., Greaves, M. J., Boyle, J. M., & Birch, J. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204369 · Cited by 62
Self-citationToffoli, G., Biason, P., Russo, A. G., Mattia, E. D., Cecchin, E., Hattinger, C. M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2249 · Cited by 61
p53 mutation does not affect prognosis in ovarian epithelial malignancies
Fallows, S., Price, J., Atkinson, R., Johnston, P. G., Hickey, I., & Russell, S. E. H. (2001) · The Journal of Pathology · doi:10.1002/path.857 · Cited by 61
A porcine model of osteosarcoma
Saalfrank, A., Janssen, K., Ravon, M., Flisikowski, K., Eser, S., Steiger, K., Flisikowska, T., Müller-Fliedner, P., Schulze, É. A., Brönner, C., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.19 · Cited by 58
Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo
Caldas, H., Holloway, M. P., Hall, B. M., Qualman, S. J., & Altura, R. A. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.034686 · Cited by 55
Tomlinson, I. P. M., Roylance, R. R., & Houlston, R. S. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.2.81 · Cited by 56
Basal p53 expression is indispensable for mesenchymal stem cell integrity
Boregowda, S. V., Krishnappa, V., Strivelli, J., Haga, C. L., Booker, C. N., & Phinney, D. G. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-017-0004-4 · Cited by 53
The Role of P53 in Human Cancer
Malkin, D. M. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010636426860 · Cited by 52
PRINCIPLES OF WILMS' TUMOR BIOLOGY
Coppes, M. J., & Pritchard‐Jones, K. (2000) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70090-2 · Cited by 52
Sutter, J. A., & Grimberg, A. (2006) · PubMed · Cited by 51
TP53-Associated Pediatric Malignancies
Pinto, E. M., Ribeiro, R. C., de Figueiredo, B. C., & Zambetti, G. P. (2011) · Genes & Cancer · doi:10.1177/1947601911409745 · Cited by 49
Identification of tumour-associated and germ line p53 mutations in canine mammary cancer
Veldhoen, N., Watterson, J., Brash, M., & Milner, J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690709 · Cited by 48
Hereditary breast cancer syndromes and genetic testing
Rich, T. A., Woodson, A., Litton, J. K., & Arun, B. K. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23791 · Cited by 48
Genetic modeling of Li-Fraumeni syndrome in zebrafish
Parant, J. M., George, S. A., Holden, J. A., & Yost, H. J. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003749 · Cited by 46
Cancer Risk Assessment Using Genetic Panel Testing: Considerations for Clinical Application
Hiraki, S. C., Rinella, E. S., Schnabel, F. R., Oratz, R., & D, H. O. M. (2014) · Journal of Genetic Counseling · doi:10.1007/s10897-014-9695-6 · Cited by 49
Quaternary structure of the specific p53–DNA complex reveals the mechanism of p53 mutant dominance
Aramayo, R. J., Sherman, M. B., Brownless, K., Lurz, R., Okorokov, A. L., & Orlova, E. V. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr386 · Cited by 46
Genetically engineered mouse models and human osteosarcoma
Ng, A. J., Mutsaers, A. J., Baker, E. K., & Walkley, C. R. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-19 · Cited by 45
Corso, G., Roncalli, F., Marrelli, D., Carneiro, F., & Roviello, F. (2012) · BioMed Research International · doi:10.1155/2013/385132 · Cited by 44
DisruptingTP53 in mouse models of human cancers
Parant, J. M., & Lozano, G. (2003) · Human Mutation · doi:10.1002/humu.10186 · Cited by 47
TP53, hChk2, and the Li-Fraumeni Syndrome
Varley, J. M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-328-3:117 · Cited by 43
Self-citationChromosome instability and deregulated proliferation: an unavoidable duo
Coschi, C. H., & Dick, F. A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0910-4 · Cited by 40
Stein, T., Crighton, D., Boyle, J. M., Varley, J. M., & White, R. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205372 · Cited by 37
Self-citationHereditary Breast Cancer in the Han Chinese Population
Cao, W., Wang, X., & Li, J. (2013) · Journal of Epidemiology · doi:10.2188/jea.je20120043 · Cited by 37
Kichina, J. V., Rauth, S., Gupta, T. K. D., & Gudkov, A. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206741 · Cited by 33
Gallo, C. V. D. M., Mendonça, G. A. E. S., de Moraes, E., Olivier, M., & Hainaut, P. L. (2005) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2005.01.002 · Cited by 35
West, A. N., Ribeiro, R. C., Jenkins, J., Galindo, C. R., de Figueiredo, B. C., Kriwacki, R. W., & Zambetti, G. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4580 · Cited by 32
Suzuki, K., Dashzeveg, N. K., Lu, Z., Taira, N., Miki, Y., & Yoshida, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02362.x · Cited by 32
Overexpression of p53 protein in human tumors
Inoue, K., Kurabayashi, A., Shuin, T., Ohtsuki, Y., & Furihata, M. (2012) · Medical Molecular Morphology · doi:10.1007/s00795-012-0575-6 · Cited by 29
Cancer initiation with epistatic interactions between driver and passenger mutations
Bauer, B., Siebert, R., & Traulsen, A. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.05.018 · Cited by 30
BRCA1/P53: Two strengths in cancer chemoprevention
Raimundo, L., Ramos, H., Loureiro, J. B., Calheiros, J., & Saraiva, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188339 · Cited by 30
Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes
Testa, J. R., Malkin, D. M., & Schiffman, J. D. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.81 · Cited by 29
Childhood predictive genetic testing for Li–Fraumeni syndrome
Evans, D. G., Lunt, P. W., Clancy, T., & Eeles, R. A. (2009) · Familial Cancer · doi:10.1007/s10689-009-9245-9 · Cited by 29
Self-citationFunctional analysis of p53 tumor suppressor in yeast
Šmardová, J., Šmarda, J., & Koptíková, J. (2005) · Differentiation · doi:10.1111/j.1432-0436.2005.00028.x · Cited by 29
p53: Multiple Facets of a Rubik's Cube
Zhang, Y., & Lozano, G. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121926 · Cited by 27
Rai, R., Tewari, M., Mohan Kumar, H., Singh, A. K., & Shukla, H. S. (2010) · European Journal of Cancer Prevention · doi:10.1097/cej.0b013e328341e371 · Cited by 26
Increased risk of breast cancer development after diagnosis of salivary gland tumour
der Maur, C. D. I., Klokman, W. J., van Leeuwen, F. E., Tan, I. B., Rutgers, E. J. T., & Balm, A. J. M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.023 · Cited by 26
Resistance of mitochondrial p53 to dominant inhibition
Heyne, K., Schmitt, K., Mueller, D., Armbruester, V., Mestres, P., & Roemer, K. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-54 · Cited by 28
Zhang, H., Yang, X., Wang, K., Tan, W., Li, H., Zuo, X., & Wen, J. (2007) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2007.09.012 · Cited by 25
The Preventive Intervention of Hereditary Breast Cancer
Cao, A., Huang, L., & Shao, Z. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_3 · Cited by 25
Hansson, J. (2008) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.04.005 · Cited by 23
Metadata
- Authors
- Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M.
- Affiliations
- Royal Manchester Children's Hospital (GB)
- Cancer Research UK Manchester Institute (GB)
- Venue
- Oncogene
- Published
- 1998-09-03
- Volume
- 17
- Issue
- 9
- Pages
- 1061-1068
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2051611229
- Cited by
- 200
- References
- 0
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 7 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 5 · 2016: 7 · 2015: 3 · 2014: 8 · 2013: 8 · 2012: 15
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- Li-Fraumeni syndrome, TP53 mutation, missense mutations, DNA-binding domain, cancer susceptibility, cancer incidence, age at diagnosis, breast cancer, brain tumors, gain-of-function, dominant negative mutation
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, DNA Mutational Analysis, Family, Family Health, Female, Genotype, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Pedigree, Phenotype, Cohort Studies, Chi-Square Distribution, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Germ-Line Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review